TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20590588

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (0.2 mg x kg(‐1)) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxycodone after inhibition of CYP2D6 (with quinidine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxycodone after inhibition of CYP3A (with ketoconazole)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18657487

Group type: EXPERIMENTAL
Intervention: Family-based GP-mediated intervention
Number of subjects: 9685

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 9685
Study: 15795705

Group type: EXPERIMENTAL
Intervention: 25 mg losartan
Number of subjects: 33

Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 50 mg losartan
Number of subjects: 33
Study: 11850708

Group type: EXPERIMENTAL
Intervention: Heparin plus ursodiol
Number of subjects: 165

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 165
Study: 10614959

Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (Filgrastim; Roche, Switzerland)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7807033

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1778219

Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT)/LCT emulsion (Lipofundin MCT 20%)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) fat emulsion (Intralipid 20%)
Number of subjects: 6
Study: 6168121

Group type: EXPERIMENTAL
Intervention: 5 mg Gutron twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31675922

Group type: EXPERIMENTAL
Intervention: New diagnostic criteria for GDM (2013 WHO criteria)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Old diagnostic criteria for GDM
Number of subjects: 2
Study: 28396242

Group type: EXPERIMENTAL
Intervention: Corticosteroid plus lidocaine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 400
Study: 25985241

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (7000 IU/d)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/d)
Number of subjects: 44
Study: 22941193

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO(3)) 0.3 g kg(‐1)
Number of subjects: 12
Study: 21459941

Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/day (MLN200:MLN200)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Milnacipran 150 mg/day (PBO:MLN150)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Milnacipran 100 mg/day (PBO:MLN100)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Milnacipran 200 mg/day (PBO:MLN200)
Number of subjects: 468
Study: 18304542

Group type: EXPERIMENTAL
Intervention: Metformin 2,000 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 17929538

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 15153259

Group type: EXPERIMENTAL
Intervention: Mediterranean‐type diet
Number of subjects: 212

Group type: COMPARATOR
Intervention: Low-fat/cholesterol diet
Number of subjects: 212
Study: 11510873

Group type: EXPERIMENTAL
Intervention: Low intensity handgrip exercise (25% of maximum voluntary contraction)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High intensity handgrip exercise (75% of maximum voluntary contraction)
Number of subjects: 28
Study: 9647682

Group type: EXPERIMENTAL
Intervention: Object-to-position-assignment condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Positional reconstruction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dual task during encoding with concurrent articulatory suppression
Number of subjects: 40
Study: 7972347

Group type: EXPERIMENTAL
Intervention: Brofaromine 50 mg/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Brofaromine 100 mg/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Brofaromine 150 mg/day
Number of subjects: 47

Group type: COMPARATOR
Intervention: Tranylcypromine 20 mg/day
Number of subjects: 47
Study: 2661738

Group type: EXPERIMENTAL
Intervention: BCNU alone
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Alternating courses of BCNU and procarbazine
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: BCNU plus hydroxyurea alternating with procarbazine plus VM‐26
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Whole-brain irradiation (6020 rads) concurrent with chemotherapy
Number of subjects: 571

Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (4300 rads) plus coned down boost (1720 rads)
Number of subjects: 571
Study: 31250043

Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Number of subjects: 44
Study: 28681424

Group type: EXPERIMENTAL
Intervention: Protected Engagement Time (PET) wards
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-PET wards
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both PET and Non-PET wards
Number of subjects: 10
Study: 26821769

Group type: EXPERIMENTAL
Intervention: 0.5 kg/mg ketamine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.2 kg/mg ketamine
Number of subjects: 48

Group type: COMPARATOR
Intervention: normal saline (NS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.5 kg/mg ketamine and 0.2 kg/mg ketamine
Number of subjects: 48
Study: 24627208

Group type: EXPERIMENTAL
Intervention: Relevant training regimen (T1 practice for both paradigms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irrelevant training regimen (comparable sensorimotor training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual-search training regimen (Exp. 2 only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 0
Study: 21934534

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol gel (1 g/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oral estradiol combined with medroxyprogesterone acetate (MPA; 5 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 20738047

Group type: EXPERIMENTAL
Intervention: Diabetes screening during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No routine screening
Number of subjects: 0
Study: 18632657

Group type: EXPERIMENTAL
Intervention: TA haplotype (codons 486 and 1822)
Number of subjects: 1399

Group type: EXPERIMENTAL
Intervention: TT-AA diplotype (codons 486 and 1822)
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Common SNPs at codons 486, 1678, 1822, 1960, and 2502
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Advanced metachronous lesions
Number of subjects: 1399
Study: 16212580

Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gingivectomy (GV)
Number of subjects: 15
Study: 11513771

Group type: EXPERIMENTAL
Intervention: Lichtenstein tension‐free hernioplasty (LH) using polypropylene prosthetic materials
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional Bassini hernia (BH) repair
Number of subjects: 35
Study: 9441137

Group type: EXPERIMENTAL
Intervention: Auto-CPAP
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional CPAP
Number of subjects: 25
Study: 8487512

Group type: EXPERIMENTAL
Intervention: Health-related fitness classroom instruction (exposed to health fitness topics on a one or two day per week basis)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (engaged strictly in skill activities daily)
Number of subjects: 90
Study: 3695656

Group type: EXPERIMENTAL
Intervention: Self-completion of MHIQ
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Telephone interview of MHIQ
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Personal interview of MHIQ
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Self-completion, telephone interview, or personal interview of MHIQ
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Physical function scores
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Social and emotional function scores
Number of subjects: 96
Study: 2689375

Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Stimulus control
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31958526

Group type: EXPERIMENTAL
Intervention: Lido/Epi:NaHCO3 mixing ratio 3:1 (IMP1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lido/Epi:NaHCO3 mixing ratio 9:1 (IMP2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Unbuffered Lido/Epi (IMP3)
Number of subjects: 48

Group type: COMPARATOR
Intervention: NaCl 0.9% (IMP4, placebo)
Number of subjects: 48
Study: 30571543

Group type: EXPERIMENTAL
Intervention: Combination of pyridostigmine 60 mg and atomoxetine 18 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atomoxetine 18 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pyridostigmine 60 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27863845

Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TREX ranibizumab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control fellow eyes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab (among patients with baseline MA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TREX ranibizumab (among patients with baseline MA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control fellow eyes (among patients with baseline MA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Incidence of new MA development
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baseline FCT and SHRM thickness
Number of subjects: 60
Study: 26049922

Group type: EXPERIMENTAL
Intervention: Trimetazidine (35 mg twice daily)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ranolazine (375 mg twice daily for 4 weeks, then 500 mg twice daily)
Number of subjects: 56
Study: 23193211

Group type: EXPERIMENTAL
Intervention: 9 dispersed boluses of 2 IU
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1 bolus of 18 IU
Number of subjects: 12
Study: 21797667

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.1% eye drops twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo eye drops administered to the other eye twice daily
Number of subjects: 20
Study: 19538912

Group type: EXPERIMENTAL
Intervention: University Assistance Program
Number of subjects: 265

Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 265
Study: 16048742

Group type: EXPERIMENTAL
Intervention: Exercise intervention (specific details not provided)
Number of subjects: 82
Study: 15100679

Group type: EXPERIMENTAL
Intervention: Inactivated trivalent split-virus influenza vaccine
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroids (ICS)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Medium-dose or high-dose inhaled corticosteroids (ICS) or oral corticosteroids
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Low-dose inhaled corticosteroids (ICS)
Number of subjects: 294
Study: 11250990

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 278

Group type: COMPARATOR
Intervention: External-beam radiotherapy
Number of subjects: 278

Group type: COMPARATOR
Intervention: Comparison of HRQOL
Number of subjects: 278
Study: 9012901

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5‐1.0 MAC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous sedatives (fentanyl/midazolam)
Number of subjects: 40
Study: 8195672

Group type: EXPERIMENTAL
Intervention: 300 U/kg r‐HuEPO on days 1, 4, 7, 10
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 400 U/kg r‐HuEPO on days 1, 5, 9
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 600 U/kg r‐HuEPO on days 1, 10
Number of subjects: 24
Study: 3148127

Group type: EXPERIMENTAL
Intervention: Topical mupirocin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Systemic erythromycin
Number of subjects: 59
Study: 31595704

Group type: EXPERIMENTAL
Intervention: Tablet formulation (R)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Disintegrating tablet formulation (T)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both formulations (R and T)
Number of subjects: 54
Study: 30722063

Group type: EXPERIMENTAL
Intervention: Intravenous UAG infusion (1 µg/kg/h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 27282755

Group type: EXPERIMENTAL
Intervention: Lowered baseline eGFR <70 mL/min per 1.73 m2
Number of subjects: 171536

Group type: EXPERIMENTAL
Intervention: Combined model of seven risk factors
Number of subjects: 171536

Group type: EXPERIMENTAL
Intervention: eGFR alone
Number of subjects: 171536
Study: 25575896

Group type: EXPERIMENTAL
Intervention: Continuous fascia iliaca compartment block (CFICB), n = 25
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous femoral nerve block (CFNB), n = 25
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison of CFICB and CFNB
Number of subjects: 50
Study: 23404097

Group type: EXPERIMENTAL
Intervention: Monetary incentives of $100/quarter for viral load suppression
Number of subjects: 80

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 80
Study: 21689438

Group type: EXPERIMENTAL
Intervention: Asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter)
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg once daily)
Number of subjects: 977

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 977
Study: 19173791

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% ophthalmic solution
Number of subjects: 21

Group type: COMPARATOR
Intervention: Artificial tears (placebo)
Number of subjects: 21
Study: 16872952

Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard cardiopulmonary bypass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 12555833

Group type: EXPERIMENTAL
Intervention: Alumina ceramic bearings
Number of subjects: 0
Study: 10657867

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No G-CSF (Control)
Number of subjects: 88
Study: 9305321

Group type: EXPERIMENTAL
Intervention: 500 mg citicoline
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: 2000 mg citicoline
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Citicoline (all doses)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 8312736

Group type: EXPERIMENTAL
Intervention: Caffeine and alcohol intake (heavy users)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 735
Study: 3524588

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 23
Study: 28914726

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia specific to bipolar disorder (CBTI‐BP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 22
Study: 27401418

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 211
Study: 25379415

Group type: EXPERIMENTAL
Intervention: Dorsal LPFC activity during cognitive control of emotional information
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: DLPFC activity during cognitive control of emotional information
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 22098090

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (200 g/d for 9 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional yoghurt (200 g/d for 9 weeks)
Number of subjects: 70
Study: 20484538

Group type: EXPERIMENTAL
Intervention: PEEP ventilation with 5 cm H(2)O (S5)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PEEP with 10 cm H(2)O (S10)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 20 degrees Trendelenburg tilt position with PEEP of 0 cm H(2)O (T0)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 20 degrees Trendelenburg tilt position combined with PEEP of 5 cm H(2)O (T5)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 20 degrees Trendelenburg tilt position combined with PEEP of 10 cm H(2)O (T10)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control condition (S0)
Number of subjects: 50
Study: 17287908

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (MK-4, menatetrenone) 45 mg/day
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 15962850

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melagatran/ximelagatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin (implied control)
Number of subjects: 0
Study: 12139543

Group type: EXPERIMENTAL
Intervention: nCPAP at 5 cm H2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: nCPAP at 10 cm H2O
Number of subjects: 10
Study: 9459316

Group type: EXPERIMENTAL
Intervention: Very-low-dose warfarin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7657419

Group type: EXPERIMENTAL
Intervention: Wash Riding (WR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-Wash Riding (NWR)
Number of subjects: 10
Study: 2650797

Group type: EXPERIMENTAL
Intervention: TP-5 50 mg three times a week for 3 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 937989

Group type: EXPERIMENTAL
Intervention: Exercise group (23 mothers)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group 1 (21 mothers)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group 2 (59 mothers)
Number of subjects: 103
Study: 31844649

Group type: COMPARATOR
Intervention: Course only (C-group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Internship only (I-group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Course and internship (CI-group)
Number of subjects: 75
Study: 27667025

Group type: EXPERIMENTAL
Intervention: 1 g of l-citrulline and 1 g of l-arginine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 g of l-citrulline or l-arginine
Number of subjects: 0
Study: 26695998

Group type: EXPERIMENTAL
Intervention: Apligraf
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EpiFix
Number of subjects: 100

Group type: COMPARATOR
Intervention: SWC
Number of subjects: 100

Group type: COMPARATOR
Intervention: EpiFix vs SWC
Number of subjects: 100

Group type: COMPARATOR
Intervention: Apligraf vs SWC
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Apligraf vs EpiFix
Number of subjects: 100
Study: 25311447

Group type: EXPERIMENTAL
Intervention: Oral vitamin D(3) 5000 IU daily
Number of subjects: 172

Group type: COMPARATOR
Intervention: Oral vitamin D(3) 600 IU daily
Number of subjects: 172
Study: 21787035

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Internal attributions of blame
Number of subjects: 203
Study: 20580618

Group type: EXPERIMENTAL
Intervention: GAD-alum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17609429

Group type: EXPERIMENTAL
Intervention: Miglustat
Number of subjects: 36

Group type: COMPARATOR
Intervention: Imiglucerase
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Miglustat alone or in combination with imiglucerase
Number of subjects: 36

Group type: COMPARATOR
Intervention: Combination therapy (Miglustat + Imiglucerase)
Number of subjects: 36
Study: 16054737

Group type: EXPERIMENTAL
Intervention: Stretching program (3 times a week for 8 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 19
Study: 12377902

Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Nonoperative treatment (ice, elevation, and rest)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Operative treatment (for patients not receiving Workers' Compensation)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Operative treatment (for women)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Operative treatment (for younger patients <29 years old with specific fracture characteristics)
Number of subjects: 424
Study: 10199877

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Nonischemic etiology of heart failure
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Ischemic heart disease
Number of subjects: 471
Study: 7552124

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach with conventional suture fixation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach with stapler fixation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach with conventional suture fixation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach with stapler fixation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional abdominal Burch colposuspension
Number of subjects: 20
Study: 1298802

Group type: EXPERIMENTAL
Intervention: Precurved endosonic files
Number of subjects: 36

Group type: COMPARATOR
Intervention: Straight endosonic files
Number of subjects: 36
Study: 6383832

Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg kg-1 i.v. on admission followed by 120 mg perorally t.i.d. for 6 months)
Number of subjects: 1436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 1436
Study: 31770371

Group type: EXPERIMENTAL
Intervention: CHIRPY DRAGON intervention (12-month programme with 4 school- and family-based components)
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: CHIRPY DRAGON intervention
Number of subjects: 1641